Intrahepatic doxorubicin in unresectable hepatocellular carcinoma. The unfavorable role of cirrhosis

M. Tommasini, M. Colombo, A. Sangiovanni, S. Orefice, P. Bignami, R. Doci, L. Gennari

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To investigate the relationship between the presence of cirrhosis and the antitumor effects of locoregional chemotherapy with doxorubicin, 16 patients with nonresectable hepatocellular carcinoma (HCC) and satisfactory baseline clinical conditions (Child class A or B, Karnofsky index > 70%) were studied. Eight patients had post-necrotic cirrhosis, five had serum HBsAg. The dose of doxorubicin was 0.3 mg/kg body weight/day, given by continuous intracoeliac infusion for 8 consecutive days. Eight patients (six with cirrhosis) died prematurely after the first course of chemotherapy. Six (2 with cirrhosis) responded to therapy; they survived 3-33 months (median: 10). In these patients, the type and severity of drug-related side effects were comparable to those reported for patients treated by intravenous chemotherapy. The implication that in many patients with cirrhosis intrahepatic chemotherapy with doxorubicin may hasten death, lessens our interest in its use for nonresectable HCC. In fact, in Italy these cancers frequently occur in association with cirrhosis.

Original languageEnglish
Pages (from-to)8-11
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume9
Issue number1
Publication statusPublished - 1986

Fingerprint

Doxorubicin
Hepatocellular Carcinoma
Fibrosis
Drug Therapy
Karnofsky Performance Status
Hepatitis B Surface Antigens
Drug-Related Side Effects and Adverse Reactions
Italy
Body Weight
Serum
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Intrahepatic doxorubicin in unresectable hepatocellular carcinoma. The unfavorable role of cirrhosis. / Tommasini, M.; Colombo, M.; Sangiovanni, A.; Orefice, S.; Bignami, P.; Doci, R.; Gennari, L.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 9, No. 1, 1986, p. 8-11.

Research output: Contribution to journalArticle

@article{c38ff46fcf684cd686ea6602fc0f0cfb,
title = "Intrahepatic doxorubicin in unresectable hepatocellular carcinoma. The unfavorable role of cirrhosis",
abstract = "To investigate the relationship between the presence of cirrhosis and the antitumor effects of locoregional chemotherapy with doxorubicin, 16 patients with nonresectable hepatocellular carcinoma (HCC) and satisfactory baseline clinical conditions (Child class A or B, Karnofsky index > 70{\%}) were studied. Eight patients had post-necrotic cirrhosis, five had serum HBsAg. The dose of doxorubicin was 0.3 mg/kg body weight/day, given by continuous intracoeliac infusion for 8 consecutive days. Eight patients (six with cirrhosis) died prematurely after the first course of chemotherapy. Six (2 with cirrhosis) responded to therapy; they survived 3-33 months (median: 10). In these patients, the type and severity of drug-related side effects were comparable to those reported for patients treated by intravenous chemotherapy. The implication that in many patients with cirrhosis intrahepatic chemotherapy with doxorubicin may hasten death, lessens our interest in its use for nonresectable HCC. In fact, in Italy these cancers frequently occur in association with cirrhosis.",
author = "M. Tommasini and M. Colombo and A. Sangiovanni and S. Orefice and P. Bignami and R. Doci and L. Gennari",
year = "1986",
language = "English",
volume = "9",
pages = "8--11",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Intrahepatic doxorubicin in unresectable hepatocellular carcinoma. The unfavorable role of cirrhosis

AU - Tommasini, M.

AU - Colombo, M.

AU - Sangiovanni, A.

AU - Orefice, S.

AU - Bignami, P.

AU - Doci, R.

AU - Gennari, L.

PY - 1986

Y1 - 1986

N2 - To investigate the relationship between the presence of cirrhosis and the antitumor effects of locoregional chemotherapy with doxorubicin, 16 patients with nonresectable hepatocellular carcinoma (HCC) and satisfactory baseline clinical conditions (Child class A or B, Karnofsky index > 70%) were studied. Eight patients had post-necrotic cirrhosis, five had serum HBsAg. The dose of doxorubicin was 0.3 mg/kg body weight/day, given by continuous intracoeliac infusion for 8 consecutive days. Eight patients (six with cirrhosis) died prematurely after the first course of chemotherapy. Six (2 with cirrhosis) responded to therapy; they survived 3-33 months (median: 10). In these patients, the type and severity of drug-related side effects were comparable to those reported for patients treated by intravenous chemotherapy. The implication that in many patients with cirrhosis intrahepatic chemotherapy with doxorubicin may hasten death, lessens our interest in its use for nonresectable HCC. In fact, in Italy these cancers frequently occur in association with cirrhosis.

AB - To investigate the relationship between the presence of cirrhosis and the antitumor effects of locoregional chemotherapy with doxorubicin, 16 patients with nonresectable hepatocellular carcinoma (HCC) and satisfactory baseline clinical conditions (Child class A or B, Karnofsky index > 70%) were studied. Eight patients had post-necrotic cirrhosis, five had serum HBsAg. The dose of doxorubicin was 0.3 mg/kg body weight/day, given by continuous intracoeliac infusion for 8 consecutive days. Eight patients (six with cirrhosis) died prematurely after the first course of chemotherapy. Six (2 with cirrhosis) responded to therapy; they survived 3-33 months (median: 10). In these patients, the type and severity of drug-related side effects were comparable to those reported for patients treated by intravenous chemotherapy. The implication that in many patients with cirrhosis intrahepatic chemotherapy with doxorubicin may hasten death, lessens our interest in its use for nonresectable HCC. In fact, in Italy these cancers frequently occur in association with cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=0022633612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022633612&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 8

EP - 11

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -